- Report
- April 2025
- 175 Pages
Global
From €3985EUR$4,490USD£3,462GBP
- Report
- September 2025
- 250 Pages
Global
From €3985EUR$4,490USD£3,462GBP
- Report
- May 2025
- 106 Pages
Global
From €4215EUR$4,750USD£3,662GBP
- Report
- August 2020
- 250 Pages
Saudi Arabia
From €3195EUR$3,600USD£2,776GBP
- Report
- August 2024
- 150 Pages
Global
From €3328EUR$3,750USD£2,891GBP
- Drug Pipelines
- July 2024
- 150 Pages
Global
From €3328EUR$3,750USD£2,891GBP
- Report
- February 2024
- 181 Pages
Europe
From €4215EUR$4,750USD£3,662GBP
- Report
- February 2024
- 150 Pages
Global
From €4215EUR$4,750USD£3,662GBP
- Report
- February 2024
- 143 Pages
Global
From €4215EUR$4,750USD£3,662GBP
- Report
- February 2024
- 85 Pages
North America
From €4215EUR$4,750USD£3,662GBP
- Report
- February 2024
- 120 Pages
Global
From €4215EUR$4,750USD£3,662GBP
- Report
- February 2024
- 70 Pages
New Zealand
From €4215EUR$4,750USD£3,662GBP
- Report
- February 2024
- 80 Pages
Europe
From €4215EUR$4,750USD£3,662GBP
- Report
- February 2024
- 90 Pages
Asia Pacific
From €4215EUR$4,750USD£3,662GBP
- Report
- February 2024
- 70 Pages
Indonesia
From €4215EUR$4,750USD£3,662GBP
- Report
- February 2024
- 70 Pages
Philippines
From €4215EUR$4,750USD£3,662GBP
- Report
- February 2024
- 70 Pages
India
From €4215EUR$4,750USD£3,662GBP
- Report
- February 2024
- 70 Pages
New Zealand
From €4215EUR$4,750USD£3,662GBP
- Report
- February 2024
- 90 Pages
South Korea
From €4215EUR$4,750USD£3,662GBP
- Report
- February 2024
- 90 Pages
United States
From €4215EUR$4,750USD£3,662GBP

Humulin is a brand of insulin used to treat endocrine and metabolic disorders. It is a recombinant human insulin, produced by genetically engineered bacteria, and is used to treat diabetes mellitus. It is available in several forms, including short-acting, intermediate-acting, and long-acting. Humulin is used to control blood sugar levels in people with type 1 and type 2 diabetes. It is also used to treat other endocrine and metabolic disorders, such as hyperglycemia, hypoglycemia, and polycystic ovary syndrome.
Humulin is a widely used insulin, and is available in many countries around the world. It is available in both generic and branded forms, and is available in both injectable and oral forms. It is also available in combination with other medications, such as metformin and glipizide.
The Humulin market is highly competitive, with many companies offering their own versions of the drug. Some of the major companies in the market include Eli Lilly, Novo Nordisk, Sanofi, Merck, and Pfizer. Show Less Read more